Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 1702–1704.

https://doi.org/10.1182/blood-2022-167931

Published: 2022

Journal Articles

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Blood (2022) 140 (Supplement 1): 9773–9775.

https://doi.org/10.1182/blood-2022-169213

Published: 2022

Journal Articles

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Courtney D. DiNardo, Nicholas Short, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Joby Joseph, Jane Waukau, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 9771–9772.

https://doi.org/10.1182/blood-2022-170138

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4036–4038.

https://doi.org/10.1182/blood-2022-170069

Published: 2022

Journal Articles

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

Jayastu Senapati, Nicholas Short, Abhishek Maiti, Hussein A Abbas, Naval Daver, Naveen Pemmaraju, Sherry A. Pierce, Kelly S. Chien, Koji Sasaki, Danielle Hammond, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 1427–1429.

https://doi.org/10.1182/blood-2022-169934

Published: 2022

Journal Articles

A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Daniel Nguyen, Elias Jabbour, Nicholas Short, Ghayas C. Issa, Musa Yilmaz, Naval Daver, Naveen Pemmaraju, Kelly S. Chien, Lucia Masarova, Farhad Ravandi, Nitin Jain, Wuliamatu Deen, Min Zhao, Christopher Loiselle, Lourdes Waller, Glenda Banks, Rebecca Garris, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 6127–6129.

https://doi.org/10.1182/blood-2022-167883

Published: 2022

Journal Articles

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Sai Prasad Desikan, Naval Daver, Sanam Loghavi, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Sherry A. Pierce, Keyur P. Patel, Hussein A Abbas, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 11788–11790.

https://doi.org/10.1182/blood-2022-166655

Published: 2022

Journal Articles

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2007–2009.

https://doi.org/10.1182/blood-2022-157210

Published: 2022

Journal Articles

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Nitin Jain, Elias Jabbour, Ibrahim Aldoss, Marina Konopleva, Nicholas Short, Anthony S. Stein, Naveen Pemmaraju, Philip A. Thompson, Farhad Ravandi, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 521–522.

https://doi.org/10.1182/blood-2022-170730

Published: 2022

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

Blood (2022) 140 (Supplement 1): 8973–8975.

https://doi.org/10.1182/blood-2022-157323

Published: 2022

Journal Articles

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Blood (2022) 140 (Supplement 1): 8966–8968.

https://doi.org/10.1182/blood-2022-157358

Published: 2022

Journal Articles

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Tareq Abuasab, Srdan Verstovsek, Gautam Borthakur, Rashmi Kanagal-Shamanna, Keyur Patel, Koichi Takahashi, Lucia Masarova, Prithviraj Bose, John Villarreal, Sherry A. Pierce, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Nicholas Short, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 8954–8956.

https://doi.org/10.1182/blood-2022-165455

Published: 2022

Journal Articles

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Blood (2022) 140 (Supplement 1): 6206–6208.

https://doi.org/10.1182/blood-2022-165359

Published: 2022

Journal Articles

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, Jon A Hernandez, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, William G. Wierda

Blood (2022) 140 (Supplement 1): 238–240.

https://doi.org/10.1182/blood-2022-170030

Published: 2022

Journal Articles

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 534–536.

https://doi.org/10.1182/blood-2022-164922

Published: 2022

Journal Articles

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up

Blood (2022) 140 (Supplement 1): 9005–9007.

https://doi.org/10.1182/blood-2022-162918

Published: 2022

Journal Articles

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Nicholas Short, Yesid Alvarado, Jan A. Burger, Nitin Jain, Marina Konopleva, Farhad Ravandi, Courtney D. DiNardo, Lucia Masarova, Koji Sasaki, Philip A. Thompson, Alessandra Ferrajoli, Jovitta Jacob, Ejiroghene Mayor, Anna Milton, Christopher Loiselle, Rebecca Garris, Hagop Kantarjian, Elias Jabbour

Blood (2022) 140 (Supplement 1): 3253–3255.

https://doi.org/10.1182/blood-2022-170667

Published: 2022

Journal Articles

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results

Blood (2022) 140 (Supplement 1): 3250–3252.

https://doi.org/10.1182/blood-2022-167761

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only